Abeona Therapeutics
ABEO
40 hedge funds and large institutions have $52.5M invested in Abeona Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 6 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
39% more capital invested
Capital invested by funds: $37.9M → $52.5M (+$14.7M)
8% more funds holding
Funds holding: 37 → 40 (+3)
0.75% more ownership
Funds ownership: 49.64% → 50.39% (+0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.63M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.39M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.88M |
| 4 |
Millennium Management
New York
|
+$1.14M |
| 5 |
Citigroup
New York
|
+$946K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.5M |
| 2 |
Goldman Sachs
New York
|
-$860K |
| 3 |
VF
Virtu Financial
New York
|
-$130K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$64.6K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$10.3K |
ABEO Hedge Fund Activity: Q3 2023 in Review
40 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2023, worth a combined $52.5M — up 39% from $37.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ABEO positions and 6 closed out — a net gain of 3 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $5.63M. The largest seller was Deerfield Management, exiting entirely with an estimated $3.5M sold.
- 40 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2023, up from 37 in Q2 2023.
- Funds reported $52.5M of Abeona Therapeutics stock for Q3 2023, up 39% quarter-over-quarter.
- 9 funds opened new Abeona Therapeutics positions in Q3 2023 and 6 closed out, a net change of +3 holders.
- The largest Abeona Therapeutics buyer in Q3 2023 was Adage Capital Partners, an estimated $5.63M added.
- The largest Abeona Therapeutics seller in Q3 2023 was Deerfield Management, an estimated $3.5M sold.
Based on aggregated 13F filings for Q3 2023.